Find an expert

Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical practice.

Dr Saunus has an honours degree in biochemistry and biomedical science, a PhD in breast cancer molecular genetics, and broad post-doctoral experience in immunology, molecular cell biology, pathology informatics, and early-phase investigator-initiated clinical trials. Her current portfolio focuses finding new ways to improve the clinical management of aggressive breast cancer, with a focus on triple-negative breast cancer, and the prevention and treatment of brain metastases. This work spans across multiple disciplines and capabilities, and broadly involves:

• Molecular profiling of patient-donated blood and tumour tissue samples to identify features that can predict treatment response, or represent previously uncharacterised therapeutic targets.
• Using experimental models of breast cancer metastasis to learn about the molecular mechanisms exploited by cancer cells to survive and grow in brain tissue.
• Developing innovative treatment strategies that work differently to conventional cancer drugs, including alpha-particle endoradiotherapy and in-situ vaccination.

With an outstanding network of collaborators from academia and clinical practice, she has secured more than $6M to fund this work and has a track record of publishing in prominent biomedical research journals (e.g., Cancer Research, Nature, Science Translational Medicine, Nature Communications and The Journal of Pathology).

Peripherally, Jodi is a strong proponent of biospecimen banking, and clinician and consumer engagement in translational research.

Professor Mark Schembri is a prominent microbiologist with experience in combating the global health crisis presented by multi-drug resistant pathogens. Professor Schembri’s expertise on the virulence of bacterial pathogens and his innovative analysis of biofilm formation aims to improve the outcomes of the >400 million individuals that suffer from urinary tract infections each year across the globe.

Through the application of genetic, genomic and functional studies on uropathogenic E. coli, Professor Schembri has identified targets to reduce the virulence of this pathogen, and will pursue the development of life-saving therapeutic and preventative advances with the assistance of NHMRC, MRFF and ARC grants. Professor Schembri has tracked the rapid emergence and global spread of a virulent, drug-resistant E. coli clone and used genome sequencing to understand its evolution and virulence.

Links: Professor Schembri collaborates with national and international research leaders, including in Denmark, where he was a lecturer. Professor Schembri has strong links with other international experts in his field, including at the Pasteur Institute and the Wellcome Trust Sanger Institute in Cambridge. His research collaborations also span lead groups at UQ and other top Australian institutes, including Griffith and La Trobe Universities.

Membership, Funding and patents: Since 2014, Professor Schembri has been awarded over $15 million in funding from competitive national research funding bodies. He holds provisional patents for the development of novel therapeutic agents and vaccine antigens. He is a Fellow of the American Academy of Microbiology, and is regularly invited to speak at international conferences in his field.

Awards and Communication: Professor Schembri was the recipient of the Frank Fenner Award (2010) and the ASM BacPath Oration Award (2019) for his outstanding original research contribution to the study of Infectious Disease. He was an Australian Research Council Future Fellow (2011-2015) a National Health and Medical Research Council Senior Research Fellow (2016-2020). Professor Schembri is the author of >240 peer-reviewed research manuscripts. He is President of the Australian Society for Microbiology (2022-2026).

Professor Kate Schroder heads the Inflammasome Laboratory and is Director of the Centre for Inflammation and Disease Research at the Institute for Molecular Bioscience (IMB), University of Queensland, as an NHMRC Leadership Fellow. Kate’s graduate studies defined novel macrophage activation mechanisms and her subsequent postdoctoral research identified surprising inter-species divergence in the inflammatory programs of human versus mouse macrophages. As an NHMRC CJ Martin Fellow in Switzerland, Kate trained with the pioneer of inflammasome biology, Jürg Tschopp. The IMB Inflammasome Laboratory, which Kate heads, investigates the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and mechanisms of inflammasome inhibition by cellular pathways and small molecule inhibitors.

Kate is a co-inventor on patents for small molecule inhibitors of the NLRP3 inflammasome, currently under commercialisation by Inflazome Ltd. Inflazome Ltd was recently acquired by Roche in a landmark deal – one of the largest in Australian and Irish biotech history. The acquisition gives Roche full rights to Inflazome’s portfolio of inflammasome inhibitors. Two of the company’s drug candidates are in clinical trials for the treatment of debilitating conditions such as cardiovascular disease, arthritis and neurodegenerative diseases such as Parkinson’s, Alzheimer’s and motor neuron disease.

Kate has authored more than 140 publications, featuring in journals such as Science, Cell, Nature Genetics, Nature Medicine, Nature Chemical Biology, Journal of Experimental Medicine and PNAS USA, and her work has been cited more than 35,000 times. Kate is an Editorial Board Member for international journals including Science Signaling, Clinical and Translational Immunology and Cell Death Disease. She is the recipient of the 2022 Women in Technology Excellence in Science Award, 2020 Nancy Mills Award for Women in Science, 2019 ANZSCDB Emerging Leader Award, 2019 Merck Research Medal, 2014 Milstein Young Investigator Award, 2013 Tall Poppy Award, 2012 Gordon Ada Career Award, 2010 QLD Premier’s Postdoctoral Award, and the 2008 Society for Leukocyte Biology’s Dolph Adams Award.

INFLAMMASOME LABORATORY RESEARCH

During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives diseases such as gout, diabetes, neurodegenerative disease and cancer. The Inflammasome Lab is defining the molecular and cellular processes of inflammation. We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.

The Inflammasome Laboratory integrates molecular and cell biology approaches with in vivo studies to gain a holistic understanding of inflammasome function during infection, and inflammasome dysfunction in human inflammatory disease. Current research interests include the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and inflammasome suppression by autophagy and small molecule inhibitors.

Dr. Helena Schuch is a senior research fellow at the School of Dentistry, University of Queensland.

She is a dentist and an oral epidemiologist with special interest in social epidemiology. Helena is also interested in methods to estimate causal inference and on applying machine learning techniques to predict oral health outcomes.

She completed her PhD in Oral Epidemiology at the University of Adelaide (2018) and is currently in the Editorial Board of Community Dentistry and Oral Epidemiology.

Qualifications: BDS, MScDent, PhD

Research Interests: Oral health inequalities. Life course epidemiology. Causal inference methods. Machine learning applied to oral health.

Associate Professor Jessica Schults is a Principal Research Fellow with the The University of Queensland School of Nursing, Midwifery and Sociall Work and the Herston Infectious Diseases Institute, Metro North Health. She is an NHMRC Emerging Leadership Fellow whose research focuses on reducing the burden of healthcare-associated infections. Jessica leads the NHMRC-funded REBUILD program, a national learning health system initiative designed to strengthen infection prevention and control across Australian healthcare services. She is Co-Principal Investigator of the MRFF-funded IVCare adaptive platform trial, and leads the first international living evidence synthesis for prevention of central line-associated bloodstream infection. A former paediatric intensive care nurse, Jessica has established a multidisciplinary research program spanning clinical trials, epidemiology, evidence synthesis, implementation science, consumer engagement, and policy translation. Her work is focused on generating evidence that is capable of delivering measurable improvements in patient outcomes and health system performance.

Jessica has strong national and international partnerships with healthcare consumers, clinicians, policymakers, professional organisations, and health services. She provides expert advice to government (ACSQHC technical advisor) and healthcare organisations on infection prevention and control and holds leadership roles across critical care and infection prevention societies, research networks and NGOs (board director ANZ Intensive Care Fouondation). She is committed to building research capacity and supporting the next generation of clinician-researchers.

Dr Tom Schultz is a molecular immunologist and early career researcher at the UQ Frazer Institute who studies the molecular and cellular biology of innate immune receptors. His research primarily focuses on molecular mechanisms of Toll-like receptor (TLR) signalling in the context of mycobacterial and Gram-negative bacterial infection of macrophages.

I graduated with a degree in Chemical Engineering and Science in 2000 from The University of Queensland, after which I joined Proteome Systems, an Australian biotechnology company. In 2004 I moved to the ETH Zurich in Switzerland for my doctoral studies. I joined the School of Chemistry & Molecular Biosciences as a University of Queensland Postdoctoral Research Fellow in 2008 and NHMRC Career Development Fellow in 2012. I am now Associate Professor in Biochemistry.

Ian Scott is the Director of Internal Medicine and Clinical Epidemiology at the Princess Alexandra Hospital and a Professor with the Faculty of Medicine. He is a consultant general physician with clinical interests in in health services evaluation and improvement, clinical guidelines, clinical decision-making, evidence-based medicine, low value care, quality use of medicines, non-invasive cardiology, advance care planning, and older patient care. He chaired the Queensland Clinical Networks Executive 2022-2024, is the inaugural chair of the Australian Deprescribing Network (2014-2023), Metro South Clinical AI Working Group, and Queensland Health Sepsis AI Working Group (both ongoing) and is a founding member of the Australian and New Zealand Affiliate of the US Society to Improve Diagnosis in Medicine (ANZA-SIDM). He was also a member of Queensland Health System Quality, Safety and Performance Management Committee (2022-2024) and the Quality and Safety Committee (2015-2020) and the Digital Health Advisory Group of the Royal Australasian College of Physicians (RACP - ongoing). He is a past President of the Internal Medicine Society of Australia and New Zealand (2003-2005) and past member of the MBS Review Taskforce for Cardiac Services (2017-2019). He has led multi-site quality improvement collaboratives in acute cardiac care including both hospitals and Divisions of General Practice. He has been involved at senior level on various high-level committees in establishing policies for Queensland Health and/or RACP on electronic discharge summaries, clinical handover, clinical indicators, evaluation of physician performance, chronic disease management, perioperative medicine, medical assessment and planning units, and patient flow through emergency departments. He has published over 300 peer-reviewed articles, presented to over 170 national and international meetings, and is a recipient of several NHMRC and government research grants.

Senior clinical pharmacist with 3 decades of experience in many facets of the pharmaceutical industry in both Australia and the UK- including work for Queensland Health as clinical pharmacist, clinical educator and team leader, National Prescribing Service academic detailer, Australian Pharmacy Council subject matter expert, Kidney Health Australia clinical advisory committee, CARI guideline working group member, Advanced Pharmacy Australia (AdPha) leadership group chair, and working as a community pharmacist and Home Medicines Review facilitator and provider.

Dr Anuj Sehgal completed his at the Roslin Institute, University of Edinburgh (UK) (2013-2017), where he developed a long-term research passion for investigating the development and function of the immune system. In 2018, Dr Sehgal joined the Mater Research Institute as a Research Officer. Some key highlights of Anuj's work has identified unique associations between macrophages and stem cell niches across the body, including intestinal stem cells (Sehgal et al., 2018, Nat. Comms) and HSC-niches in the bone marrow and peripheral lymphoid organs (Kaur*, Sehgal* et al. 2021 J. Hem. Onco). In 2022, Anuj diverted from academic research to contract clinical trials at the Wesley Research Institute. More recently, Anuj has rejoined UQ as a Flow Cytometry research fellow in the Chappell Lab under the ViceBio team, working on cell mediated immune responses in RSV preclinical and clinical trials.

Dr Tanuka Sen is a Research Fellow at the Institute for Molecular Biosciences, The University of Queensland, where her research focuses on understanding bacterial pathogenesis and developing innovative strategies to combat antimicrobial resistance.

Dr. Sen completed her PhD in Biochemistry and Biomedical Science at the Australian National University before undertaking postdoctoral research at the University of Oxford, where she developed single-cell microscopy approaches to visualise the dynamics of bacterial virulence plasmids in real time. She has contributed to research on bacterial toxin-antitoxin systems, plasmid biology, antimicrobial resistance, and genome analysis.

Her research integrates microbiology, molecular biology, bacterial genetics, advanced fluorescence microscopy, bioinformatics, and antimicrobial drug discovery to investigate bacterial virulence, plasmid biology, host-pathogen interactions, and the mechanisms of action of novel antimicrobial compounds. She is particularly interested in translating fundamental discoveries into new approaches to combat antibiotic-resistant pathogens.

Research expertise includes:

• Antimicrobial resistance (AMR)
• Antimicrobial drug discovery and mode of action
• Bacterial pathogenesis and virulence
• Infection biology
• Fluorescence and confocal microscopy
• Single-cell and live-cell imaging
• Functional genomics and bioinformatics
• Plasmid biology and horizontal gene transfer
• Bacterial genetics and molecular microbiology

She welcomes opportunities for interdisciplinary research, student supervision, industry engagement, and collaborations that advance antimicrobial innovation and improve global health.

Dr Abbas Shafiee is leading a multidisciplinary program in Regenerative Dermatology and Biofabrication. His research integrates stem cell biology, organoid technology, and bioengineering to develop advanced human models and regenerative therapies for skin repair and disease.

Dr Shafiee completed his PhD in stem cell biology, discovering a previously unknown vascular stem cell population, termed the Meso-Endothelial Bipotent Progenitor, and mapping its molecular signatures (Stem Cell Reports 2018). This seminal discovery advanced the understanding of human vascular development and regeneration.

He subsequently joined Distinguished Professor Dietmar Hutmacher’s group, where he developed humanised tissue-engineered bone and tumour models that mimic cancer metastasis and tumor–stroma interactions. These models (International Journal of Cancer (2018), Biomaterials (2018, 2020), and Bone Research (2019), Acta Biomaterialia (2020), Bone (2022)) provided unprecedented insights into human-specific cancer biology and preclinical drug testing.

Dr Shafiee joined Metro North Health (MNH) in 2020 to lead a research program and develop, implement, and evaluate the applications of 3D printing, scanning, cell therapies, and biofabrication technologies in skin wound settings, and dermatology research. His team has developed vascularised and immune-integrated skin organoids and 3D-printed bioengineered grafts that accelerate wound closure with minimal scarring (Biomaterials 2021; Advanced Healthcare Materials (2022; 2025); Small 2024; Burns & Trauma 2025). These breakthroughs underpin new patient-specific skin disease models, and drug screening platforms (Acta Biomaterialia 2025). He is the lead inventor on an international patent protecting an Optimized Method for Generating Human Skin Organoids (WO/2025/097221), which forms the foundation for emerging commercial and translational partnerships. This body of work led to the establishment of the International Consortium for Organoid Research in Dermatology, a global network accelerating discovery and translation in skin biology, rare genetic skin diseases, and regenerative dermatology.

Dr Shafiee has secured >AUD $2.4M as Chief Investigator (>AUD $1.1M as CIA) in competitive research funding from national, international, philanthropic, and industry-supported schemes. Dr Shafiee has supervised more than ten PhD, Masters, honours students and contributed to multiple professional, editorial, and scientific leadership roles. He has authored over 88 peer-reviewed publications (>5,500 citations, h-index 40) and delivered more than 50 invited, keynote, and plenary presentations internationally. He serves on multiple professional and editorial boards, including Australian Wound & Tissue Repair Society (AWTRS), Burns & Trauma, and Engineered Regeneration. In recognition of his pioneering contributions to regenerative medicine and science communication, he has received multiple honours, including the 2024 Frazer Institute Rising Star Award, the 2025 AWTRS EMCR Award, and the 2025 Queensland Young Tall Poppy Science Award, and selection as a 2026 TEDx speaker, recognising his leadership in translating complex science to global audiences.

He actively engages with the media, schools, and community programs to inspire future scientists and raise public awareness of regenerative medicine and organoid technologies. His outreach has reached millions nationwide through major media coverage (e.g., The Australian, 7NEWS, ABC NEWS) .

Research areas:

• Human iPSC-derived skin organoids and skin-on-chip models
• Vascularization and immune integration in skin tissue engineering
• Rare genetic skin diseases and personalized regenerative therapies
• Translational biofabrication and wound healing technologies
• Organoid-based preclinical drug discovery platforms

Honours, Masters, and PhD opportunities are available for motivated students interested in regenerative dermatology, biofabrication, and organoid biology.

I am an Aboriginal woman from the Ngen'giwumirri language group (Daly River, Northern Territory), born in Brisbane and connected to Indigenous communities across South East Queensland. I currently hold the position of Professor and Deputy Head of School in the School of Education at The University of Queensland. My research program is nationally and internationally recognised, with a focus on Indigenous education, codesign in Indigenous education, Indigenous participation in STEM, youth studies, flexi schooling, and education policy. I lead an extensive externally funded research program, including Australian Research Council (ARC) grants and government tenders, and I actively contribute to policy development through advisory roles at both state and national levels. I am a Chief Investigator on the ARC Centre of Excellence for Indigenous Futures.

I am committed to advancing strengths-based approaches in Indigenous education. My scholarship includes over 100 publications, and I have co-edited two major texts in the field. The first, “Indigenous Education in Australia: Learning and Teaching for Deadly Futures” (Routledge, 2021), which received a national award at the Education Publishing Awards Australia. My most recent book, “Strengths-Based Approaches to Indigenous Education Research and Practice” (Routledge, 2025), co-edited with Professor Grace Sarra, further contributes to the growing body of work that centres Indigenous voices and leadership in education. My academic work builds on my foundation as a qualified, Queensland-registered secondary school teacher.

Throughout my career, I have received multiple awards in recognition of research excellence and leadership, including the UQ Foundation Research Excellence Award (2021), the UQ Award for Excellence in Graduate Research Leadership (2024), and the National ACEL Leadership Award (2020). As a qualified and experienced secondary teacher, I remain deeply committed to research translation and applied research that support advancing educational equity. I designed a specialised program aimed at growing the Indigenous Education research workforce, the SoE DEADLY Community, providing mentoring to early career researchers and supervising Indigenous higher degree research students through the creation of an environment that centres Indigenous strengths, knowledges and aspirations.

My work continues to be driven by a belief in the transformative power of education and the importance of Indigenous-led research and practice, underpinned by Indigenous-informed evidence, and a commitment to bridging research, policy and practice.

Dr Shakti Shrestha is Deputy Director of Research and Lecturer in Pharmacy Practice and Medicines Management at the School of Pharmacy and Pharmaceutical Sciences, The University of Queensland (UQ). His research program focuses on optimising medication use in older people and those with life‑limiting illness, with particular interests in deprescribing, medication safety, dementia and palliative care, quality use of medicines, and the implementation of evidence into practice.

Shakti conceived and co‑led the development of De‑TOPPLE, a deprescribing decision‑support framework designed to improve medication optimisation for older adults with limited life expectancy. He also served as a Research Fellow and Queensland site coordinator for the MRFF‑funded EMBRACE trial, evaluating strategies to enhance the implementation of evidence‑based psychotropic prescribing recommendations in Australian residential aged care. His broader research spans medicines optimisation, medication‑related quality of life, pharmacy practice, health services research, and implementation science, forming a coherent program aimed at reducing medication‑related harm and improving care outcomes for older populations, particularly those with palliative care needs.

He has published widely across ageing, medication safety, deprescribing and pharmacy practice, and received the 2025 Best Publication by an Early Career Researcher Award from the UQ School of Pharmacy and Pharmaceutical Sciences. He supervises PhD, postgraduate and undergraduate research projects in medicines optimisation, polypharmacy, deprescribing and medication use in older populations, integrating his research expertise into teaching and research training.

Shakti’s academic and research work is informed by extensive experience across pharmacy practice, clinical research, residential aged care and higher education in Australia, the United Kingdom and Nepal. He was awarded the 2018 Australian Research Training Scholarship for his PhD in Clinical Pharmacy and Pharmacy Practice at UQ and the 2022 Career Development Scholarship, through which he gained further clinical trail experience across Queensland Hospital and Health Services. He holds a Master of Science in Clinical Pharmacology with Distinction from the University of Aberdeen (UK), and Bachelor of Pharmaceutical Sciences with Distinction from Pokhara University (Nepal). During his Master's training in the UK, he gained research experience working with SITS-ISTR (Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Registry) data within NHS Grampian.

Dr Kirstine Shrubsole is an NHMRC Emerging Leadership Fellow at the Queensland Aphasia Research Centre. She holds a Bachelor of Speech Pathology (First Class Honours) from The University of Queensland, and completed her PhD in 2018. Kirstine has a research focus on improving implementation of evidence into practice in speech pathology and multidisciplinary services, with a special interest in stroke and aphasia rehabilitation. She has demonstrated that practice change is achievable for healthcare teams working in aphasia, leading to positive outcomes for patients, clinicians, and organisations.

Kirstine has published over 60 peer-reviewed journal articles, and has been awarded over $14 million in competitive research funding. Kirstine previously worked as the Conjoint Research Fellow in Speech Pathology (Princess Alexandra Hospital and The University of Queensland), providing research capacity building and mentoring to speech pathologists and supporting multidisciplinary research. Kirstine is the co-founder and Deputy Lead of the Collaboration of Aphasia Triallists’ Implementation Science in Aphasia working group, and a research affiliate of the Centre for Research Excellence in Aphasia Rehabilitation and Recovery.

Kirstine is completing a NHMRC Emerging Leadership Fellowship on the following topic:

• The Aphasia Implementation Toolkit Project: Developing an implementation intervention to improve services for stroke survivors with aphasia

She is a chief investigator on three MRFF grants, including:

• Unspoken, Unheard, Unmet: Improving Access to Preventative Health Care through Better Conversations about Care

• Bridging the Digital Divide: Building Health Self-Efficacy through Communication-Accessible Online Environments

• Enhancing utility of neuropsychological evaluation for earlier and effective diagnosis of dementia in Parkinson's disease

PLEASE NOTE THAT ANY AUTHORSHIP ALTERATIONS LISTING ME AS SIMPSON-FRASER BELOW ARE INCORRECT. ALL PUBLICATIONS ARE FIONA SIMPSON. MY PROFESSIONAL NAME IS FIONA SIMPSON.

https://www.abc.net.au/radionational/programs/ockhamsrazor/the-tricky-business-of-cancer-research/9498246

Our laboratory is involved in cross-discipline research studying endocytosis, cancer, pharmacology and immunology to improve therapies used in cancer treatment.

Peter Simpson is a recognised expert in the molecular and pathological characterisation of breast and lung cancers. His research is based at the UQ Centre for Clinical Research (UQCCR), where he is the Head of the Cancer Theme and is a Research Group Leader in Cancer Genomics. He has published >150 articles (>12,000 citations, H-index 52; Scopus, May2025) including in Nature, Nature Medicine, Annals of Oncology and the American Journal of Respiratory and Critical Care Medicine. He co-manages the Brisbane Breast Bank (BBB), a tissue bank created to facilitate clinical breast cancer research, and the Debutant lung cancer Program.

Pete also holds a teaching appointment in UQ, where he is passionate about the science and clinical applications of Pathology. He teaches into the UQ Medical Program (Year 1 and 2), as well as to undergraduates. He has co-authored a chapter ‘Breast Diseases’ in the latest edition (11th) of the internationally acclaimed Medical text book Robbins and Cotran Pathologic Basis of Disease.

Outside UQ, Pete is a Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia (FFSc RCPA), a member of the kConFab Executive (https://www.kconfab.org/), a member of the Lobular Breast Cancer Alliance Scientific Advisory Board (https://lobularbreastcancer.org/), and a member of the International Cancer Genome Consortium (Breast Cancer group).

Pete enjoys supervising students at all levels in their careers and collaborating within multidisciplinary teams spanning clinical (e.g. pathology, oncology) and science teams (e.g. in ‘omics, bioinformatics and machine learning).

Professor Peter Sly is the Director, Children's Health and Environment Program. Professor Sly is a NHMRC Leadership Fellow (L3) and an emeritus paediatric respiratory physician with extensive research experience in respiratory physiology, developmental immunology and children's environmental health. Professor Sly’s research aims to understand the mechanisms underlying chronic childhood lung diseases in order to improve clinical management and to delay or prevent their onset, with consequent reductions in adult lung diseases. A combination of basic science, longitudinal cohort studies and translation of research findings into clinical practice, including clinical trials, are included in three main areas: asthma, cystic fibrosis and children’s environmental health

Professor Sly is an advisor to the World Health Organisation Department of Public Health, Environmental and Social Determinants of Disease and currently serves on International Advisory Boards and committees, including: WHO network of Collaborating Centres in Children’s Environmental Health; Canadian Healthy Infant Longitudinal Development (CHILD) Study, Canada; the Infant Lung Health Study, Paarl, South Africa; and A SHARED Future: Achieving Strength, Health, and Autonomy, through Renewable Energy Development for the Future.